BRIEF—Lilly agrees collaboration with ImmuNext in autoimmune diseases

Eli Lilly has agreed terms for a global licensing and research collaboration with ImmuNext, focused on the study of a novel preclinical target with potential in autoimmune diseases.

ImmuNext will receive $40 million upfront, and up to approximately $565 million in development and commercialization milestones, plus tiered royalties.

Lilly gains an exclusive, global license to develop and commercialize the novel immunometabolism target. The firms will establish a three-year research collaboration to support the target's development.